As a fast-growing company, BioLizard has been recognised as one of the companies to watch in 2025!
This recognition is part of a joint initiative by Trends, Change the Game, and Kanaal Z, which closely monitors companies achieving the greatest growth based on value creation, expanding and knowledgeable workforces.
We are thrilled about this nomination and proud to be seen as a source of energy and inspiration for entrepreneurs.
Well done BioLizard team
BioLizard is proud to have received the Best Poster Award at the European Society for Spatial Biology (ESSB) conference, recognising our work on benchmarking cell segmentation methods for single-cell spatial transcriptomics.
Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their operations and unlock greater value from their data.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
